Stay updated with breaking news from Nasdaq Fdmt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Rating)’s share price was up 7.5% on Friday after Bank of America raised their price target on the stock from $28.00 to $33.00. The stock traded as high as $21.29 and last traded at $20.99. Approximately 73,528 shares changed hands during mid-day trading, a decline of 85% from […]
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Rating)’s share price gapped up prior to trading on Thursday after Bank of America raised their price target on the stock from $28.00 to $33.00. The stock had previously closed at $18.27, but opened at $20.85. 4D Molecular Therapeutics shares last traded at $20.23, with a volume of […]
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Rating) insider Scott Bizily sold 2,247 shares of the company’s stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $18.31, for a total value of $41,142.57. Following the completion of the sale, the insider now owns 1,737 shares […]
Reported data from cohort 1 (n=3, 1E15 vg dose) of cystic fibrosis modulator treatment ineligible/intolerant participants with 9-12 months follow-up ...
Opaleye Management Inc. decreased its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Rating) by 5.9% during the 4th quarter, Holdings Channel reports. The fund owned 330,000 shares of the company’s stock after selling 20,700 shares during the quarter. 4D Molecular Therapeutics makes up 2.5% of Opaleye Management Inc.’s portfolio, making the stock its […]